Eli Lilly’s stock gains after positive Phase 3 data for its oral diabetes drug Foundayo boosts market confidence in the treatment’s outlook.
Eli Lilly (LLY) shares rose 2.16% to $1,155.84 on Monday, extending a weekly gain to 4.62%. The increase follows the release of robust Phase 3 trial data for Foundayo (orforglipron), the company’s oral diabetes treatment, at the American Diabetes Association’s 86th Scientific Sessions.
The trial results exceeded expectations, reinforcing investor optimism about Foundayo’s potential in the diabetes market. Prior to the announcement, Lilly’s stock had shown steady growth, reflecting broader confidence in its pipeline. The data release aligns with the company’s strategic focus on expanding its diabetes portfolio.
Markets reacted positively to the news, with LLY shares continuing their upward trajectory in early trading.